Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131144 | 0.98 | CCR6 (0.47) | CCR6CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL21282988 | 0.96 | CCR6 (0.45) | CCR6CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL13436278 | 0.87 | CCR6 (0.46) | CCR6CHKA | |
| SCHEMBL13436522 | 0.86 | CCR6 (0.47) | CCR6CHRNB2CHRNA4MKNK1MKNK2 | |
| SCHEMBL13436280 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL13436487 | 0.86 | KDM4E (0.41) | CCR6CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL13436500 | 0.86 | HRH4 (0.44) | CCR6 | |
| SCHEMBL13436267 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL13436507 | 0.84 | CCR6 (0.51) | CCR6CHRNB2CHRNA4MKNK1MKNK2 | |
| SCHEMBL13436330 | 0.84 | KDM4E (0.45) | CCR6CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCR6 4225/4885CHRNB2 388/4885CHRNA4 459/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCR6 4225/4885CHRNB2 388/4885CHRNA4 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.